← Human Trials & Peer-Reviewed Studies

The effects of two different intensities of aerobic training protocols on pain and serum neuro-biomarkers in women migraineurs: a randomized controlled trail

Plain-language guide to PMID 33206251 (2021): randomized controlled trial study of PACAP, migraine.

Key Facts

PMID
33206251
Journal
European journal of applied physiology
Year
2021
Study type
Randomized Controlled Trial
Authors
Eslami R et al. (5 authors)
DOI
10.1007/s00421-020-04551-x

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of PACAP in the context of migraine, published as a randomized controlled trial.

The researchers have a weak understanding of how aerobic training may influence migraine, and the optimal parameters for exercise regimens as migraine therapy are not clear.

The objectives of this study were to assess, first, effects of two different intensities of aerobic exercise on migraine headache indices; second, serum neuro-biomarker in women migraineurs.

Who Took Part

By PubMed's age tags, the people studied were adults, women only.

A total of 45 non-athlete female migraine patients were selected by a neurologist and randomly divided into three groups: control (CON), moderate-intensity aerobic training (MOD T), and high-intensity aerobic training (HIGH T).

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got PACAP and who got the comparison, which limits bias.

Before and after the training protocol, body composition factors, migraine pain indices, VO2max, and serum Adenylate-Cyclase Activating Polypeptide (PACAP) and Substance P (SP) were measured.

What Was Measured

The subject headings attached to it are Biomarkers, Exercise, Migraine Disorders, Oxygen, Pain and Pituitary Adenylate Cyclase-Activating Polypeptide.

The authors tagged it with the keywords Adenylate-cyclase activating polypeptide (PACAP), Aerobic training and Substance P (SP).

What This Means in Plain Language

The paper is a randomized study of PACAP in people with migraine.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (European journal of applied physiology), a journal based in Germany.

More context: the PACAP compound page, Migraine research.

Our Notes on the Compound

PACAP: Pituitary adenylate cyclase-activating polypeptide, a 38-amino-acid neuropeptide studied in migraine provocation research.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.